Annexon, Inc. (ANNX) NASDAQ

5.45

+0.01(+0.18%)

Updated at May 13 04:00PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Douglas Love	Chief Executive Officer, President & Director	1.06M	1968
Michael Overdorf	Executive Vice President & Chief Business Officer	580,469	1971
Jennifer Lew	Executive Vice President, Chief Financial Officer & Corporate Secretary	700,017	1973
Jamie Dananberg	Executive Vice President & Chief Medical Officer	715,233	1958
Ted Yednock	Executive Vice President, Chief Innovation Officer & Chairman of the Scientific Advisory Board	737,794	1958
Dean R. Artis	Chief Scientific Officer & Executive Vice President	797,380	1961
Lloyd Clark	Senior Vice President of Ophthalmology Strategy & Innovation	0	N/A
Henk-Andre Kroon	Senior Vice President of Translational Medicine	0	N/A
Shikhar Agarwal	Senior Vice President & Head of Commercial	0	N/A
Sunil Mehta	Senior Vice President of Medical Affairs	0	N/A

Name

Title

Pay

Year Born

Douglas Love

Chief Executive Officer, President & Director

1.06M

1968

Michael Overdorf

Executive Vice President & Chief Business Officer

580,469

1971

Jennifer Lew

Executive Vice President, Chief Financial Officer & Corporate Secretary

700,017

1973

Jamie Dananberg

Executive Vice President & Chief Medical Officer

715,233

1958

Ted Yednock

Executive Vice President, Chief Innovation Officer & Chairman of the Scientific Advisory Board

737,794

1958

Dean R. Artis

Chief Scientific Officer & Executive Vice President

797,380

1961

Lloyd Clark

Senior Vice President of Ophthalmology Strategy & Innovation

N/A

Henk-Andre Kroon

Senior Vice President of Translational Medicine

N/A

Shikhar Agarwal

Senior Vice President & Head of Commercial

N/A

Sunil Mehta

Senior Vice President of Medical Affairs

N/A

Description

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.